Cetirizine is an antihistamine. Most people know it as the active ingredient in over-the-counter allergy medications like Zyrtec. Its relevance to hair loss is less widely known, but there is a growing body of evidence that topical cetirizine, applied directly to the scalp, can slow hair loss and support regrowth in men and women with androgenetic alopecia.
Prostaglandins and Hair Loss
To understand how cetirizine works, it helps to understand the role of prostaglandins in hair follicle regulation.
Prostaglandins are signaling molecules made from fatty acids. They regulate inflammation, blood vessel dilation, and smooth muscle contraction throughout the body. In the scalp, two prostaglandins have opposite effects on hair:
- Prostaglandin D2 (PGD2): Inhibits hair growth. PGD2 is produced by
CRTH2-expressing cells and binds to the CRTH2 receptor on hair follicles. In men with androgenetic alopecia, PGD2 levels in the scalp are significantly elevated compared to areas with normal hair growth.
- Prostaglandin E2 (PGE2): Promotes hair growth. PGE2 stimulates follicle growth and appears to counteract the inhibitory effects of PGD2.
Research published in 2012 by Garza and colleagues found that PGD2 was elevated 3x as high in the bald scalp of men with androgenetic alopecia compared to hair-bearing scalp, and that
application of PGD2 to mouse skin inhibited hair regrowth. This study established PGD2 as a significant contributor to hair follicle inhibition in androgenetic alopecia.
Elevated PGD2 in the scalp actively suppresses hair growth. Blocking the pathway through which PGD2 acts on follicles is a therapeutically relevant target.
How Cetirizine Targets This Pathway
Cetirizine is an H1 antihistamine, meaning it blocks histamine receptors. Its relevance to hair loss comes from a secondary property: cetirizine also antagonizes the CRTH2 receptor, which is the receptor through which PGD2 inhibits hair follicle growth.
By blocking CRTH2, topical cetirizine reduces the inhibitory signal that PGD2 delivers to the follicle. Additionally, cetirizine may shift the prostaglandin balance more favorably by increasing
PGE2 relative to PGD2.
One study found that cetirizine significantly reduced PGD2 production by human sebocytes and upregulated PGE2 production, suggesting a dual mechanism that both reduces the inhibitory signal and enhances the growth signal at the follicle level.
Cetirizine addresses a mechanism of hair loss — the PGD2-CRTH2 pathway — that finasteride and minoxidil do not. This makes it a potentially complementary agent rather than an alternative.
Clinical Evidence for Topical Cetirizine
The clinical evidence for topical cetirizine is encouraging but still early-stage compared to the decades of data behind finasteride and minoxidil.
A 2017 double-blind randomized controlled trial published in the Journal of Dermatology enrolled 60 men with androgenetic alopecia to receive either 1% topical cetirizine or placebo daily for six months. Results showed:
- ● Significantly greater hair density in the cetirizine group at 6 months
- ● Mean hair density increased by 12.2% in the cetirizine group vs. 1.2% in placebo
- ● Investigator global assessment favored cetirizine significantly.
- ● No significant side effects were reported
A 2020 study examined the effect of a 1% cetirizine solution in 50 patients with androgenetic alopecia over a 6-month period. Results showed significant improvements in hair density, hair shaft diameter, and the percentage of hairs in the anagen phase in the cetirizine group compared with controls.
Early clinical trials show that 1% topical cetirizine produces meaningful, statistically significant improvements in hair density with a good tolerability profile.
Comparing Cetirizine to Minoxidil
A 2021 comparative study enrolled 120 patients with androgenetic alopecia and divided them into three groups: 1% topical cetirizine, 5% topical minoxidil, and a combination of both. At 6 months:
- ● 5% minoxidil: significant improvement in hair density
- ● 1% cetirizine: significant improvement, somewhat less than 5% minoxidil
- ● Combination group: significantly greater improvement than either agent alone
This study is important for two reasons. First, it confirms that cetirizine is active as a standalone treatment, though less potent than 5% minoxidil. Second, it shows that the combination is additive, suggesting that cetirizine and minoxidil work through sufficiently different mechanisms that their effects compound.
Cetirizine is less effective than 5% minoxidil as a standalone treatment but produces an additive benefit when combined with minoxidil. This positions it as a valuable adjunct in combination protocols.
Inflammation and Androgenic Alopecia
The relevance of cetirizine extends beyond its effect on the PGD2 pathway. Scalp inflammation is increasingly recognized as a contributing factor in androgenetic alopecia.
A 2004 paper by Mahe and colleagues found evidence of perifollicular inflammation in over 40% of biopsies from men with androgenetic alopecia, even in early-stage cases. This inflammation appears to accelerate follicle miniaturization and may contribute to the irreversible phase of hair follicle loss in advanced cases.
Cetirizine, as an anti-inflammatory and anti-allergic agent, reduces local scalp inflammation.
This may provide an additional benefit beyond its effect on the PGD2 pathway, reducing the inflammatory component that accelerates follicle damage.
Scalp inflammation is a co-contributor to androgenetic alopecia, often overlooked in standard treatment protocols. Cetirizine addresses this independently of its prostaglandin effects.
How to Use Topical Cetirizine
Topical cetirizine at 1% concentration is not available as a commercial FDA-approved product in the United States. It is compounded by prescription at compounding pharmacies. It is typically formulated in an aqueous solution for scalp application.
Application is usually once daily, applied to the affected scalp areas and left on. As with minoxidil, consistency of application is critical to outcomes.
Oral cetirizine at standard doses (10 mg daily) does not appear to produce the same scalp-level effects as the topical formulation. Topical delivery concentrates the drug where it is needed.
Topical 1% cetirizine requires a prescription through a compounding pharmacy. Oral antihistamines do not achieve the scalp-level concentration required for hair benefits.
The Bottom Line
Topical cetirizine at 1% addresses the PGD2-CRTH2 pathway, a mechanism of hair loss suppression that is elevated in androgenetic alopecia and not targeted by finasteride or minoxidil. Clinical trials show meaningful improvement in hair density with good tolerability. It is less effective than 5% minoxidil as a standalone treatment but produces an additive benefit when combined. Its anti-inflammatory properties may provide an additional advantage in patients with scalp inflammation as a contributing factor.